Literature DB >> 31947236

Analyzing progression of motor and speech impairment in ALS.

Carla Agurto, Omar Ahmad, Guillermo A Cecchi, Raquel Norel, Mary Pietrowicz, Elif K Eyigoz, Elizabeth Mosmiller, Emily Baxi, Jeffrey D Rothstein, Promit Roy, James Berry, Nicholas J Maragakis.   

Abstract

Amyotrophic lateral sclerosis (ALS) is a degenerative disease which causes death of neurons controlling voluntary muscles. It is currently assessed with subjective clinical measurements, but it would benefit from alternative surrogate biomarkers that can better estimate disease progression. This work analyzes speech and fine motor coordination of subjects recruited by the Answer ALS foundation using data from a mobile app. In addition, clinical variables such as speech, writing and total ALSFRS-R scores are also acquired along with forced and slow vital capacity. Cross-sectional and longitudinal analyses were performed using speech and fine motor features. Results show that both types of features are useful to infer clinical variables especially for males (R2=0.79 for ALSFRS-R total score), but their initial values are not helpful to predict speech and motor decline. However, we found that longitudinal progression for bulbar and spinal ALS onset are different and they can be identified with high accuracy by the extracted features.

Entities:  

Mesh:

Year:  2019        PMID: 31947236     DOI: 10.1109/EMBC.2019.8857300

Source DB:  PubMed          Journal:  Conf Proc IEEE Eng Med Biol Soc        ISSN: 1557-170X


  1 in total

1.  Answer ALS, a large-scale resource for sporadic and familial ALS combining clinical and multi-omics data from induced pluripotent cell lines.

Authors:  Emily G Baxi; Terri Thompson; Jonathan Li; Julia A Kaye; Ryan G Lim; Jie Wu; Divya Ramamoorthy; Leandro Lima; Vineet Vaibhav; Andrea Matlock; Aaron Frank; Alyssa N Coyne; Barry Landin; Loren Ornelas; Elizabeth Mosmiller; Sara Thrower; S Michelle Farr; Lindsey Panther; Emilda Gomez; Erick Galvez; Daniel Perez; Imara Meepe; Susan Lei; Berhan Mandefro; Hannah Trost; Louis Pinedo; Maria G Banuelos; Chunyan Liu; Ruby Moran; Veronica Garcia; Michael Workman; Richie Ho; Stacia Wyman; Jennifer Roggenbuck; Matthew B Harms; Jennifer Stocksdale; Ricardo Miramontes; Keona Wang; Vidya Venkatraman; Ronald Holewenski; Niveda Sundararaman; Rakhi Pandey; Danica-Mae Manalo; Aneesh Donde; Nhan Huynh; Miriam Adam; Brook T Wassie; Edward Vertudes; Naufa Amirani; Krishna Raja; Reuben Thomas; Lindsey Hayes; Alex Lenail; Aianna Cerezo; Sarah Luppino; Alanna Farrar; Lindsay Pothier; Carolyn Prina; Todd Morgan; Arish Jamil; Sarah Heintzman; Jennifer Jockel-Balsarotti; Elizabeth Karanja; Jesse Markway; Molly McCallum; Ben Joslin; Deniz Alibazoglu; Stephen Kolb; Senda Ajroud-Driss; Robert Baloh; Daragh Heitzman; Tim Miller; Jonathan D Glass; Natasha Leanna Patel-Murray; Hong Yu; Ervin Sinani; Prasha Vigneswaran; Alexander V Sherman; Omar Ahmad; Promit Roy; Jay C Beavers; Steven Zeiler; John W Krakauer; Carla Agurto; Guillermo Cecchi; Mary Bellard; Yogindra Raghav; Karen Sachs; Tobias Ehrenberger; Elizabeth Bruce; Merit E Cudkowicz; Nicholas Maragakis; Raquel Norel; Jennifer E Van Eyk; Steven Finkbeiner; James Berry; Dhruv Sareen; Leslie M Thompson; Ernest Fraenkel; Clive N Svendsen; Jeffrey D Rothstein
Journal:  Nat Neurosci       Date:  2022-02-03       Impact factor: 28.771

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.